Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 70%
Negative

Neutral
GlobeNewsWire
7 days ago
Enovis completes sale of its Dr. Comfort Footcare Solutions business for proceeds of up to $60 million
Wilmington, DE, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced the sale of its Dr. Comfort diabetic shoe business to Promus Equity Partners, a multi-family asset management firm based in Chicago, for consideration of up to $60 million in cash, consisting of an upfront payment of $45 million, and up to $15 million payable in the future upon the achievement of certain milestones.
Enovis completes sale of its Dr. Comfort Footcare Solutions business for proceeds of up to $60 million
Neutral
GlobeNewsWire
1 month ago
Enovis Corporation Announces Time Change for Presentation at Baird 2025 Global Healthcare Conference
Wilmington, DE, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will now present at the Baird 2025 Global Healthcare Conference at 2:35 p.m. ET on Wednesday, September 10th, 2025.
Enovis Corporation Announces Time Change for Presentation at Baird 2025 Global Healthcare Conference
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Believe Enovis (ENOV) Could Rally 69.91%: Here's is How to Trade
The consensus price target hints at a 69.9% upside potential for Enovis (ENOV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Enovis (ENOV) Could Rally 69.91%: Here's is How to Trade
Neutral
Seeking Alpha
1 month ago
Enovis: Healthy Recon Trends Vs. Market Apathy
Enovis remains out of favor despite solid results, but I still see potential for mid-single-digit revenue growth and low double-digit FCF margins long-term. The Recon business is performing well, gaining share in extremities, while P&R remains a slow-growth drag on overall performance and valuation. Tariff risks are manageable, but I'm unimpressed by the new CEO's lack of ortho experience.
Enovis: Healthy Recon Trends Vs. Market Apathy
Positive
Zacks Investment Research
1 month ago
Does Enovis (ENOV) Have the Potential to Rally 77.33% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 77.3% in Enovis (ENOV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does Enovis (ENOV) Have the Potential to Rally 77.33% as Wall Street Analysts Expect?
Neutral
GlobeNewsWire
2 months ago
Enovis to Participate in Upcoming Investor Conferences
Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:
Enovis to Participate in Upcoming Investor Conferences
Neutral
Seeking Alpha
2 months ago
Enovis Corporation (ENOV) Q2 2025 Earnings Call Transcript
Enovis Corporation (NYSE:ENOV ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Damien McDonald - CEO & Director Kyle William Rose - Vice President of Investor Relations Phillip Benjamin Berry - Senior VP & CFO Conference Call Participants Caitlin Cronin - Canaccord Genuity Corp., Research Division Dane M. Reinhardt - Robert W.
Enovis Corporation (ENOV) Q2 2025 Earnings Call Transcript
Positive
Zacks Investment Research
2 months ago
Enovis (ENOV) Beats Q2 Earnings and Revenue Estimates
Enovis (ENOV) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.62 per share a year ago.
Enovis (ENOV) Beats Q2 Earnings and Revenue Estimates
Neutral
The Motley Fool
2 months ago
Enovis (ENOV) Q2 Revenue Rises 7%
Enovis (ENOV) Q2 Revenue Rises 7%
Enovis (ENOV) Q2 Revenue Rises 7%
Neutral
GlobeNewsWire
2 months ago
Enovis Announces Second Quarter 2025 Results
Wilmington, DE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.
Enovis Announces Second Quarter 2025 Results